In NSCLC, BMs are more frequently observed in cases with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements, with over 45% of patients developing CNS involvement within the first three years of survival [13]. Here, ALK is linked to non-small cell lung carcinoma.